Literature DB >> 33290916

JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease.

Rachel Eisenberg1, Melissa D Gans2, Timothy Ronan Leahy3, Florian Gothe4, Candice Perry5, Mark Raffeld5, Liqiang Xi5, Sarah Blackstone6, Chi Ma6, Sophie Hambleton7, Joshua D Milner8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33290916      PMCID： PMC9175514          DOI： 10.1016/j.jaip.2020.11.050

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia.

Authors:  Anna Brady; Sarah Gibson; Lisa Rybicki; Eric Hsi; Yogen Saunthararajah; Mikkael A Sekeres; Ramon Tiu; Edward Copelan; Matt Kalaycio; Ronald Sobecks; Jennifer Bates; Anjali S Advani
Journal:  Eur J Haematol       Date:  2012-07-26       Impact factor: 2.997

2.  JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome.

Authors:  Kate L Del Bel; Robert J Ragotte; Aabida Saferali; Susan Lee; Suzanne M Vercauteren; Sara A Mostafavi; Richard A Schreiber; Julie S Prendiville; Min S Phang; Jessica Halparin; Nicholas Au; John M Dean; John J Priatel; Emily Jewels; Anne K Junker; Paul C Rogers; Michael Seear; Margaret L McKinnon; Stuart E Turvey
Journal:  J Allergy Clin Immunol       Date:  2017-01-19       Impact factor: 10.793

3.  A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).

Authors:  Mignon L Loh; Sarah K Tasian; Karen R Rabin; Patrick Brown; Daniel Magoon; Joel M Reid; Xuejun Chen; Charlotte H Ahern; Brenda J Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-05-13       Impact factor: 3.167

4.  The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.

Authors:  Obul R Bandapalli; Stephanie Schuessele; Joachim B Kunz; Tobias Rausch; Adrian M Stütz; Noa Tal; Ifat Geron; Nava Gershman; Shai Izraeli; Juliane Eilers; Nina Vaezipour; Renate Kirschner-Schwabe; Jana Hof; Arend von Stackelberg; Martin Schrappe; Martin Stanulla; Martin Zimmermann; Rolf Koehler; Smadar Avigad; Rupert Handgretinger; Viktoras Frismantas; Jean Pierre Bourquin; Beat Bornhauser; Jan O Korbel; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Haematologica       Date:  2014-06-27       Impact factor: 9.941

5.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Authors:  Can Küçük; Bei Jiang; Xiaozhou Hu; Wenyan Zhang; John K C Chan; Wenming Xiao; Nathan Lack; Can Alkan; John C Williams; Kendra N Avery; Pınar Kavak; Anna Scuto; Emel Sen; Philippe Gaulard; Lou Staudt; Javeed Iqbal; Weiwei Zhang; Adam Cornish; Qiang Gong; Qunpei Yang; Hong Sun; Francesco d'Amore; Sirpa Leppä; Weiping Liu; Kai Fu; Laurence de Leval; Timothy McKeithan; Wing C Chan
Journal:  Nat Commun       Date:  2015-01-14       Impact factor: 14.919

6.  Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea.

Authors:  Chi A Ma; Liqiang Xi; Brian Cauff; Adam DeZure; Alexandra F Freeman; Sophie Hambleton; Gary Kleiner; T Ronan Leahy; Maureen O'Sullivan; Michelle Makiya; Grainne O'Regan; Stefania Pittaluga; Julie Niemela; Jennifer Stoddard; Sergio D Rosenzweig; Mark Raffeld; Amy D Klion; Joshua D Milner
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

Review 7.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

8.  Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.

Authors:  Lisa R Forbes; Tiphanie P Vogel; Megan A Cooper; Johana Castro-Wagner; Edith Schussler; Katja G Weinacht; Ashley S Plant; Helen C Su; Eric J Allenspach; Mary Slatter; Mario Abinun; Desa Lilic; Charlotte Cunningham-Rundles; Olive Eckstein; Peter Olbrich; R Paul Guillerman; Niraj C Patel; Yesim Y Demirdag; Christa Zerbe; Alexandra F Freeman; Steven M Holland; Paul Szabolcs; Andrew Gennery; Troy R Torgerson; Joshua D Milner; Jennifer W Leiding
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

9.  Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.

Authors:  Nicholas C P Cross; Yvette Hoade; William J Tapper; Gonzalo Carreno-Tarragona; Tiziana Fanelli; Mohamad Jawhar; Nicole Naumann; Iwo Pieniak; Johannes Lübke; Sahra Ali; Kaljit Bhuller; Sonja Burgstaller; Catherine Cargo; Jamie Cavenagh; Andrew S Duncombe; Emma Das-Gupta; Paul Evans; Peter Forsyth; Philip George; Charlotte Grimley; Fergus Jack; Laura Munro; Varun Mehra; Kavita Patel; Ali Rismani; Gabriela Sciuccati; Rowena Thomas-Dewing; Patrick Thornton; Andres Virchis; Simon Watt; Louise Wallis; Alastair Whiteway; Kris Zegocki; Barbara J Bain; Andreas Reiter; Andrew Chase
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528
  9 in total
  2 in total

Review 1.  JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.

Authors:  Yiming Luo; Madison Alexander; Massimo Gadina; John J O'Shea; Francoise Meylan; Daniella M Schwartz
Journal:  J Allergy Clin Immunol       Date:  2021-10       Impact factor: 14.290

Review 2.  Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.

Authors:  Jérôme Hadjadj; Marie-Louise Frémond; Bénédicte Neven
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.